DOR BioPharma reports year-end financials and accomplishments, early 2006 achievements

Revenues for 2005 were $3,075,736 compared to $997,482 in 2004. The revenue in both years was due to the September 2004 $5.2 million grant award from the National Institute of Allergy and Infectious Diseases (NIAID) for RiVax, which was increased to $6.4 million in May 2005. This increase was awarded based on a new renegotiated F&A rate with the NIH which may be used for overhead expenditures.

The company's net loss for 2005 was approximately $4.7 million, or $0.09 per share, compared to $6.3 million, or $0.16 per share for 2004. The improvement in the net loss was primarily related...

Want to see the full article?

• Purchase this article for only $3.00